STRUCTURAL STUDIES OF THERAPEUTIC TARGETS IN ONCOLOGY AND INFECTIOUS DISEASE

肿瘤学和传染病治疗靶点的结构研究

• 批准号: 8170680
• 负责人: P Ann Boriack-Sjodin
• 金额: $ 0.29万
• 依托单位: BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8170680
• 关键词: Anti-Bacterial Agents; Antibiotics; Bacteria; Boston; Clinical; Communicable Diseases; Computer Retrieval of Information on Scientific Projects Database; Crystallography; Drug Design; Drug resistance; Funding; Goals; Grant; Institution; Isoenzymes; Lead; Pharmacologic Substance; Phosphotransferases; Proteins; Research; Research Personnel; Resistance; Resources; Source; Staging; Structure; Therapeutic Agents; United States National Institutes of Health; base; design; inhibitor/antagonist; novel; oncology; research and development; therapeutic target

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pharmaceutical research focusing on broad-spectrum antibiotics has declined significantly in recent years, despite the fact that drug resistance is increasing in many bacterial species. AstraZeneca is focusing its efforts in antibacterial research on novel targets with broad spectrum potential in efforts to create therapeutic agents with no cross-resistance to clinical strains of bacteria. In order to obtain these goals, protein crystallography is being utilized in most projects at all stages of the pipeline to guide inhibitor design, often with isozymes from multiple bacterial species. Protein crystallography is especially critical in the earliest stages of lead discovery, particularly with regard to fragment hits.Oncology targets at AstraZeneca R&D Boston include those accessible by structural efforts. Structure-based drug design is utilized in more than 50% of the oncology pipeline. Targets include, but are not limited to kinases, for which the wealth of available structural information from internal and external sources is critical in the design of potent and selective inhibitors.

这个子项目是众多研究子项目之一